Is Davunetide FDA approved?

Davunetide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

TRH is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Davunetide administered in research settings?

In research settings, Davunetide is typically administered via the intranasal or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is TRH administered in research settings?

In research settings, TRH is typically administered via the intranasal, intravenous, or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Davunetide vs TRH

Peptide Comparison

Davunetide vs TRH

Q: What is the difference between Davunetide and TRH?

Davunetide: Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation. TRH: Hypothalamic tripeptide (pGlu-His-Pro-NH2); binds TRH-R1/R2; stimulates TSH/prolactin release; direct CNS effects independent of thyroid axis including synaptic potentiation

Both are Neuro & Cognitive peptides.

Davunetide

NAP

CognitiveInvestigationalResearch Only

No providers listed yet

Full Davunetide profile →

TRH

Thyrotropin-Releasing Hormone

CognitiveNot EvaluatedCompoundable

Half-life: ~5-6 minutes

3 providers listed

Full TRH profile →

Bottom line

Davunetide carries stronger published evidence (RCT, 3 key studies) than TRH (RCT, 2); both are research compounds.

Quick Verdict

Davunetide

Evidence

Clinical

Half-life

—

TRH

Evidence

Emerging Clinical

Half-life

~5-6 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Davunetide
Further along in FDA review	Davunetide
More provider options (0 vs 3)	TRH

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Davunetide

TRH

Mechanism Family

Neuro & Cognitive

Half-life

—

~5-6 minutes

FDA Status

investigational

not evaluated

Admin Routes

intranasal, subcutaneous

intranasal, intravenous, subcutaneous

Availability

Research Only

Compoundable

Providers

None listed

3 listed

Avail. Notes

—

Was FDA-approved as Thypinone (NDA 017812) and Relefact TRH for diagnostic TSH testing. Both products voluntarily discontinued. Nominated on the FDA 503B outsourcing-facility list (Category 3 — nominated without adequate support to date); not on the 503A pharmacy bulk-substances list. Prescription.

Research Evidence

Davunetide

ClinicalRCT · 3 key studies · most recent 2026

TRH

Emerging ClinicalRCT · 2 key studies · dated evidence base — most recent 1997

Research Citations

Davunetide

Cohort2026 · Epilepsy Res

Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.

RCT2013 · Neuropsychopharmacology

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with sch…

RCT2011 · Schizophrenia Research

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophren…

TRH

Animal1997 · Regulatory Peptides

Thyrotropin releasing hormone prevents abnormalities of cortical acetylcholine and monoamines in mice followi…

RCT1990 · Psychopharmacology

TRH attenuates scopolamine-induced memory impairment in humans

About Davunetide

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Research Areas

neuroprotectiontau stabilizationcognitive enhancementmemorysynaptic plasticity

About TRH

Hypothalamic tripeptide (pGlu-His-Pro-NH2); binds TRH-R1/R2; stimulates TSH/prolactin release; direct CNS effects independent of thyroid axis including synaptic potentiation

Research Areas

cognitive enhancementneuroprotectionantidepressantarousal/wakefulness

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Davunetide

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

TRH

Reported (Unverified — Pending Clinical Review)

hyperthyroidismcardiac arrhythmiashypertensionepilepsy

No established clinical contraindications

Find Providers

Where to source these peptides

Providers offering

Davunetide

Browse directory →

Providers offering

TRH

3 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.